Journals / The Anatolian Journal of Cardiology / 2017 / Cilt: 17 - Sayı: 4

Inhibition of 5-lipoxygenase by zileuton in a rat model of myocardial infarction

Pages
269–275
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Zileuton had no significant effect on increased serum TNF-α levels in I/R group.Conclusion: 5-LOX inhibition in rat myocardial infarction model attenuated increased left ventricle NF-κB expression and apoptosis and these actions were not modulated by COX inhibitors

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The goal of the present study was to investigate the effects of 5-lipoxygenase (5-LOX) inhibition, alone and with cyclooxygenase (COX) inhibitors, on inflammatory parameters and apoptosis in ischemia/reperfusion (I/R)-induced myocardial damage in rats.
📊
Key Findings & Data:For this purpose, zileuton, a selective and potent inhibitor of 5-LOX, resulting in suppression leukotriene production, was used.Methods: Male Wistar rats (200-250 g; n=12 per group) were used in the study.
💡
Conclusion & Impact:Zileuton had no significant effect on increased serum TNF-α levels in I/R group.Conclusion: 5-LOX inhibition in rat myocardial infarction model attenuated increased left ventricle NF-κB expression and apoptosis and these actions were not modulated by COX inhibitors
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The goal of the present study was to investigate the effects of 5-lipoxygenase (5-LOX) inhibition, alone and with cyclooxygenase (COX) inhibitors, on inflammatory parameters and apoptosis in ischemia/reperfusion (I/R)-induced myocardial damage in rats. For this purpose, zileuton, a selective and potent inhibitor of 5-LOX, resulting in suppression leukotriene production, was used.Methods: Male Wistar rats (200-250 g; n=12 per group) were used in the study. I/R was performed by occluding the left coronary artery for 30 minutes and 2 hours of reperfusion of the heart. Experimental groups were I/R group, sham I/R group, zileuton (5 mg/kg orally, twice daily)+I/R group, zileuton+indomethacin (5 mg/kg intraperitoneally)+I/R group, zileuton+ketorolac (10 mg/kg subcutaneously)+I/R group, and zileuton+nimesulide (5 mg/kg subcutaneously)+I/R group. Following I/R, blood samples were collected to measure tumor necrosis factor alpha (TNF-α), and left ventricles were excised for evaluation of microscopic damage; malondialdehyde (MDA), glutathione, nuclear factor (NF)-κB assays; and evaluation of apoptosis.Results: Left ventricle MDA in I/R group was higher compared to sham group; however, it did not show significant change with zileuton. Although tissue injury in I/R group was less severe in all treatment groups, it was not statistically significant. NF-κB H-score and apoptotic index, which were higher in I/R group compared to sham I/R, were decreased with application of zileuton (H-score: p<0.01; apoptotic index: p<0.001). Zileuton had no significant effect on increased serum TNF-α levels in I/R group.Conclusion: 5-LOX inhibition in rat myocardial infarction model attenuated increased left ventricle NF-κB expression and apoptosis and these actions were not modulated by COX inhibitors

🔖

Cite This Article

ABUEİD, L., USLU, Ü., CUMBUL, A., ÖĞÜNÇ, A. V., ERCAN, F., ALİCAN, Y. İ. (2017). Inhibition of 5-lipoxygenase by zileuton in a rat model of myocardial infarction. The Anatolian Journal of Cardiology, Cilt: 17 - Sayı: 4, 269–275. https://ajindex.com/articles/367233

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Bagatini MD, Martins CC, Battisti V, Gasparetto D, da Rosa CS, Spanevello RM, et al. Oxidative stress versus antioxidant defenses in patients with acute myocardial infarction. Heart Vessels 2011; 26: 55-63. Henderson WR. The role of leukotrienes in inflammation. Ann In- tern Med 1994; 121: 684-97.
  2. Sasaki K, Ueno A, Katori M, Kikawada R. Detection of leukotriene B4 in cardiac tissue and its role in infarct extension through leuco- cyte migration. Cardiovasc Res 1988; 22: 142-8.
  3. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992; 85: 230-6.
  4. Hock CE, Beck LD, Papa LA. Peptide leukotriene receptor antago- nism in myocardial ischaemia and reperfusion. Cardiovasc Res 1992; 26: 1206-11.
  5. Fiedler VB, Mardin M. Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog. J Car- diovasc Pharmacol 1985; 7: 983-9.
  6. Hahn RA, MacDonald BR, Simpson PJ, Potts BD, Parli CJ. Antago- nism of leukotriene B4 receptors does not limit canine myocardial infarct size. J Pharmacol Exp Ther 1990: 253: 58-66.
  7. Shekher A, Singh M. Role of eicosanoid inhibition of ischemia re- perfusion injury: intact and isolated rat heart studies. Methods Find Exp Clin Pharmacol 1997; 19: 223-9. Wu KK. Inducible cyclooxygenase and nitric synthase. Adv Phar- macol 1995; 33: 179-207.
  8. Wong SCY, Fukuchi M, Melnyk P, Rodger A, Giaid A. Induction of cy- clooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure. Circulation 1998; 98: 100-3.
  9. Saito T, Rodger IW, Hu F, Shennib H, Giaid A. Inhibition of cyclo- oxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 2000; 273: 772-5.
  10. Hamad AM, Stcliffe AM, Knox AJ. Aspirin-induced asthma: clinical aspects, pathogenesis and management. Drugs 2004; 64: 2417-32.
  11. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mu- cosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34: 742-7.
  12. Kwak HJ, Park KM, Choi HE, Lim HJ, Park JH, Park HY. The cardio- protective effects of zileuton, a 5-lipoxygenase inhibitor, are medi- ated by COX-2 via activation of PKCdelta. Cell Signal 2010; 22: 80-7.
  13. Rossi A, Pergola C, Koeberle A, Hoffmann M, Dehm F, Bramanti P, et al. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inh